Koers Stereotaxis Inc Nasdaq
Aandelen
US85916J4094
Geavanceerde medische apparatuur & technologie
Omzet 2024 * | 30,4 mln. 28,3 mln. | Omzet 2025 * | 43,6 mln. 40,58 mln. | Marktkapitalisatie | 145 mln. 135 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -18 mln. -16,75 mln. | Nettowinst (verlies) 2025 * | -15 mln. -13,96 mln. | EV/omzet 2024 * | 4,75 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 3,32 x |
K/w-verhouding 2024 * |
-7,33
x | K/w-verhouding 2025 * |
-8
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 84,22% |
Recentste transcriptie over Stereotaxis Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Fischel
CEO | Chief Executive Officer | 57 | 29-09-16 |
Kimberly Peery
DFI | Director of Finance/CFO | 55 | 01-01-03 |
Laura Garth
LAW | General Counsel | - | 01-01-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Robert Messey
BRD | Director/Board Member | 78 | 01-05-05 |
David Fischel
CEO | Chief Executive Officer | 57 | 29-09-16 |
Nathan Fischel
BRD | Director/Board Member | 68 | 03-02-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+0,59% | 207 mld. | |
+3,92% | 181 mld. | |
+30,07% | 155 mld. | |
+32,42% | 112 mld. | |
+1,98% | 64,42 mld. | |
+19,65% | 54,38 mld. | |
-1,86% | 47,43 mld. | |
-9,53% | 37,17 mld. | |
-1,28% | 34,81 mld. |